Opening: Real Consultation Scenario
A couple sat in my consultation room. The wife placed a thick stack of test reports on the desk. "Doctor, I am 39 years old, my AMH is 1.2, FSH is 11.5, and my antral follicle count is 6. Karyotype analysis shows I am a carrier of a balanced translocation. A local doctor said I could do PGT, but after two ovarian stimulation cycles, I only got 4 eggs, none of which formed a blastocyst suitable for biopsy. Is overseas IVF PGT suitable for me?"
This is a typical PGT applicable population — carriers of chromosomal structural abnormalities, but simultaneously facing the challenge of diminished ovarian reserve. Answering the question "Who is overseas IVF PGT suitable for?" requires analysis from two dimensions: genetic indications and fertility conditions.
When is Overseas IVF PGT Suitable?
Overseas IVF PGT (Preimplantation Genetic Testing) is an embryo screening technology designed for couples with specific genetic risks. Clarifying when it is suitable and when it is not is one of the high-frequency consultation questions in reproductive clinics. PGT is currently divided into three types:
| Type | Detection Target | Main Applicable Population |
|---|---|---|
| PGT-A | Embryo chromosomal aneuploidy (numerical abnormalities) | Advanced maternal age, recurrent miscarriage, recurrent implantation failure |
| PGT-M | Monogenic diseases (e.g., thalassemia, hemophilia) | Carriers or patients with monogenic diseases |
| PGT-SR | Chromosomal structural rearrangements (balanced translocation, Robertsonian translocation, inversion, etc.) | Carriers of chromosomal structural abnormalities |
The core conditions for being suitable for PGT include: clear genetic indications, the ability to obtain a sufficient number of blastocysts for biopsy, financial affordability, and reasonable expectations regarding the benefits and limitations of PGT.
When is it not suitable: Embryo screening without clear medical indications (e.g., solely for sex selection or non-medical traits), extremely low ovarian reserve with no expectation of forming blastocysts suitable for biopsy, very low embryo count (≤2) with a high risk of no usable embryos after biopsy, and unrealistic expectations about PGT success rates.
Why is PGT Needed — The Medical Logic
The emergence of PGT technology aims to solve two core problems: first, implantation failure, miscarriage, and birth defects caused by embryonic chromosomal aneuploidy; second, the transmission of monogenic diseases to offspring. With increasing age, the error rate of oocyte meiosis rises, and the embryonic aneuploidy rate increases exponentially. At age 38, approximately 40% of embryos are aneuploid, and by age 42, this can exceed 70%.
For carriers of chromosomal structural abnormalities (e.g., balanced translocation), about 50%-70% of the embryos produced have unbalanced chromosomes, leading to recurrent miscarriage or birth defects. Carriers of monogenic diseases have a 25%-50% probability of passing the pathogenic gene to their offspring. PGT screens for genetically normal embryos at the embryonic level for transfer, reducing miscarriage rates, improving single-transfer success rates, and blocking the transmission of genetic diseases.
Module C: The Doctor's PerspectiveThe Reproductive Specialist's Decision-Making Logic
From a reproductive specialist's perspective, PGT is not a routine option for all IVF patients. The decision is made in three steps:
- Step 1: Identify genetic indications. Is the patient of advanced maternal age (≥38 years)? Is there a chromosomal structural abnormality? Is there a carrier status for a monogenic disease? Is there a history of recurrent miscarriage or previous aneuploidy pregnancy?
- Step 2: Assess fertility conditions. Can ovarian reserve (AMH, FSH, antral follicle count) support obtaining a sufficient number of eggs? Are the male semen analysis results normal? Are there any usable embryos from previous IVF cycles?
- Step 3: Choose the PGT type and testing plan. Select PGT-A, PGT-M, or PGT-SR based on the genetic issue; some cases require combined testing. Is frozen embryo transfer needed? Is genetic counseling and family verification required?
When undergoing PGT overseas, it is also necessary to consider the regulatory restrictions of the destination country, laboratory qualifications, embryo transport policies, as well as personal visa and travel arrangements.
Module D: Differences Across Age GroupsApplicability Differences Across Age Groups
Age is one of the most critical variables affecting the suitability and degree of benefit from PGT.
| Age Group | Embryo Aneuploidy Rate (Approx.) | PGT-A Benefit Assessment | Considerations |
|---|---|---|---|
| ≤35 years | 20%-30% | Limited benefit unless there are clear genetic indications or a history of recurrent miscarriage | Prioritize investigating other causes (uterine, endocrine, immune, etc.) |
| 36-37 years | 30%-40% | Can be considered, especially when combined with other risk factors | Must be assessed in conjunction with embryo count and developmental potential |
| 38-40 years | 40%-55% | Clear benefit: reduces miscarriage rate, improves single-transfer success rate | It is recommended to also assess ovarian reserve and develop an individualized ovarian stimulation protocol |
| 41-42 years | 60%-75% | Significant benefit, but attention must be paid to the number of usable embryos | May require multiple egg retrievals to accumulate embryos |
| ≥43 years | 80%-90% | Benefit exists, but egg yield and blastocyst formation rate decline significantly | Requires thorough communication, realistic expectations, and consideration of alternatives like egg donation |
It is important to note that age is only one reference indicator. Actual ovarian reserve function (AMH, antral follicle count) and previous IVF response history have a greater impact on decision-making. For patients with low AMH but younger age, PGT suitability needs to be assessed on a case-by-case basis.
Module E: Differences Across CountriesRegulatory Differences for PGT Across Countries
The suitability of overseas IVF PGT is also significantly influenced by the regulations of the destination country. The following are policy differences among major countries:
| Country/Region | Key PGT Policies | Practical Impact on Patients |
|---|---|---|
| United States | PGT-A, PGT-M, and PGT-SR are all legal; sex selection is legal; no strict medical indication required | Widest range of options, but higher cost (approx. $15,000-$30,000/cycle); patients need to arrange genetic counseling independently |
| Thailand | PGT-A is available; sex selection is legal; PGT-M requires genetic documentation | Good cost-effectiveness, well-established medical support, relatively relaxed policies |
| Japan | Only PGT for medical indications is permitted; non-medical sex selection is prohibited; requires ethics committee approval | Strict regulation, suitable for patients with clear genetic indications, but the process cycle is longer |
| Europe (most countries) | Policies vary greatly; some countries prohibit PGT-A or limit it to severe genetic diseases; sex selection is generally prohibited | Requires advance confirmation of specific regulations in the destination country; suitable for patients with clear monogenic diseases or chromosomal abnormalities |
| Malaysia/Cambodia | Relatively relaxed policies; PGT-A and sex selection are available; PGT-M requires genetic report | Moderate cost, suitable for some patients with specific needs |
When choosing an overseas PGT destination, it is recommended to prioritize laboratory qualifications, embryo biopsy and cryopreservation technology, and genetic counseling capabilities as core evaluation criteria, rather than focusing solely on policy leniency.
Module O: Suitable Populations (Detailed)Summary of Suitable Populations
Combining genetic indications and fertility conditions, the following populations are suitable for considering overseas IVF PGT:
- Women aged 38 years or older, especially those with a history of recurrent miscarriage or previous IVF failure.
- Carriers of chromosomal structural abnormalities: balanced translocation, Robertsonian translocation, inversion, insertion, etc., regardless of age.
- Carriers or patients with monogenic diseases: thalassemia, hemophilia, cystic fibrosis, spinal muscular atrophy (SMA), etc.
- History of recurrent miscarriage (2 or more), after excluding uterine anatomical, endocrine, and immune factors, considering the possibility of embryonic chromosomal abnormalities.
- History of previous aneuploidy pregnancy: such as Down syndrome, Edwards syndrome, etc., or having given birth to a child with chromosomal abnormalities.
- Male severe oligoasthenospermia or Y chromosome microdeletion, requiring PGT to screen for normal embryos.
- Recurrent implantation failure (failure of implantation after 3 or more transfers of good quality embryos), after excluding endometrial factors.
- Advanced maternal age with a desire to reduce miscarriage risk and high expectations for single-transfer success rate.
Unsuitable Populations and Common Misconceptions
PGT is not recommended or should be carefully considered in the following situations:
- No clear medical indication, solely for sex selection or non-medical traits. Most countries prohibit PGT for non-medical indications, and it is not recommended from a medical ethics perspective.
- Extremely poor ovarian reserve (AMH <0.4 ng/mL, antral follicle count <3), with no expectation of obtaining enough eggs to form blastocysts suitable for biopsy.
- Very low embryo count (egg retrieval <3 or expected blastocyst count <2), where biopsy may result in no usable embryos.
- Unrealistic expectations about PGT success rates. PGT cannot guarantee 100% healthy live birth and has limitations such as mosaicism and testing errors.
- Overinterpretation of low-risk chromosomal mosaicism, discarding usable embryos by considering low-risk mosaicism as abnormal.
- Limited financial resources, as PGT costs are high (overseas approx. $10,000-$30,000/cycle) and are usually not included in the basic IVF fee.
Common Misconceptions: "PGT can improve egg quality" — Incorrect. PGT screens embryos and cannot improve egg quality. "PGT can solve all miscarriage problems" — Incorrect. Miscarriage causes are complex; PGT only addresses embryonic chromosomal factors. "A normal PGT-A result means a healthy child" — Incorrect. PGT-A only screens for chromosomal numerical abnormalities and cannot rule out monogenic diseases, structural malformations, etc.
High-Frequency Consultation Questions
PGT-A checks whether the number of chromosomes in an embryo is normal (aneuploidy screening), suitable for advanced maternal age, recurrent miscarriage, and recurrent implantation failure. PGT-M detects specific monogenic diseases, suitable for couples known to carry pathogenic genes. They can be performed together. PGT-SR specifically targets chromosomal structural rearrangements (e.g., balanced translocation), detecting whether embryos have unbalanced chromosome segments.
PGT biopsy is usually performed at the blastocyst stage (day 5-6), taking 5-10 trophectoderm cells, which has minimal impact on the inner cell mass (which develops into the fetus). Current large-scale studies show that the blastocyst survival rate after PGT biopsy is about 90%-95%, and the live birth rate after frozen-thawed transfer is not significantly different from non-biopsied embryos. However, the biopsy procedure depends on laboratory technology and experience; choosing a qualified reproductive center is crucial.
Low AMH does not mean PGT is completely impossible, but it requires assessing egg retrieval potential and blastocyst formation rate. For patients with AMH 0.5-1.0 ng/mL, under 38 years old, and without other genetic indications, the benefit of PGT is limited; for AMH <0.5 ng/mL and age ≥40 years, PGT is usually not recommended, and priority should be given to embryo accumulation or egg donation. If there is a strong indication like chromosomal abnormality, multiple egg retrievals can be attempted to accumulate embryos for a unified biopsy.
Female examination items: AMH, FSH, LH, antral follicle count, thyroid function, infectious disease screening, karyotype analysis. Male examination items: semen analysis, sperm morphology, infectious disease screening, karyotype analysis (Y chromosome microdeletion testing if necessary). For PGT-M, a genetic disease diagnosis certificate, pathogenic gene test report, and family verification results are required. Document materials: passport (validity recommended over 6 months), visa, notarized and translated marriage certificate, and translated copies of previous medical records and test reports.
A complete cycle usually takes 2-3 months. Specific timeline: ovarian stimulation about 10-14 days, embryo culture to blastocyst after egg retrieval about 5-6 days, genetic testing after biopsy about 7-14 days (PGT-A about 7-10 days, PGT-M/PGT-SR about 10-14 days), and then frozen embryo transfer scheduled (next menstrual cycle) after results are available. Including preliminary examinations and genetic counseling, it is recommended to reserve 3-4 months overall.
It is recommended to start basic preparation 3 months before starting the cycle: supplement folic acid (400-800 μg/day), vitamin D (adjust based on serum levels), Coenzyme Q10 (200-400 mg/day to improve oocyte mitochondrial function). Lifestyle adjustments: regular routine, moderate exercise, smoking and alcohol cessation, weight control (BMI 18.5-24.0 kg/m²). Men are also advised to supplement zinc, selenium, L-carnitine, etc., to improve sperm quality. However, it must be clear: preparation cannot replace medical intervention and has limited impact on ovarian reserve and genetic issues.
Doctor's Advice
PGT is an important embryo screening technology, but it is not a universal solution. Suitability needs to be based on a comprehensive assessment of genetic counseling, fertility evaluation, and embryo developmental potential. The following are specific recommendations:
- Patients with clear genetic indications (chromosomal abnormalities, monogenic diseases, advanced maternal age, recurrent miscarriage) should evaluate PGT suitability under the guidance of a reproductive specialist and genetic counselor.
- When choosing an overseas reproductive center, focus on laboratory qualifications, PGT testing platforms (NGS, aCGH), genetic counseling team configuration, and the applicability of the destination country's regulations to your situation.
- Complete comprehensive examinations for both partners before the PGT cycle, including karyotype analysis, infectious disease screening, semen analysis, genetic counseling, and hysteroscopy if necessary to rule out endometrial factors.
- Maintain rational awareness of PGT limitations: risks such as embryo mosaicism, testing errors, and no usable embryos objectively exist. Communicate fully with your doctor and develop a backup plan.
Risk Reminder: PGT cannot eliminate all genetic risks and cannot replace prenatal diagnosis. Routine prenatal examinations (e.g., amniocentesis, ultrasound screening) are still required after transfer. Overseas IVF involves cross-border medical care; it is recommended to understand the destination's medical regulations, language communication, travel arrangements, and cost structure in advance to avoid decision-making errors due to information asymmetry.
Related Medical Entities: AMH · FSH · LH · Antral Follicle · Semen Analysis · Chromosome Testing · Genetic Counseling · Hysteroscopy · Passport · Visa · File Creation · Ovarian Stimulation · Egg Retrieval · Embryo Culture · PGT-A · PGT-M · PGT-SR · Frozen Embryo · Transfer · Luteal Support · Reproductive Specialist · Laboratory
Comments (0)